Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
17 nov. 2022 16h01 HE
|
Annexon Biosciences
BRISBANE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023
03 nov. 2022 06h30 HE
|
Annexon Biosciences
Company to provide portfolio updates across autoimmune, neurodegeneration and ophthalmology therapeutic franchises in early January Presentations at upcoming scientific conferences highlight...
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
18 oct. 2022 16h01 HE
|
Annexon Biosciences
BRISBANE, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
16 sept. 2022 16h01 HE
|
Annexon Biosciences
BRISBANE, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
17 août 2022 16h05 HE
|
Annexon Biosciences
BRISBANE, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Biosciences Highlights Business and Portfolio Progress and Key Anticipated Milestones and Reports Second Quarter 2022 Financial Results
08 août 2022 16h01 HE
|
Annexon Biosciences
Advancing Robust Pipeline of Five Clinical-Stage Product Candidates Following ANX105 and ANX1502 Phase 1 Trial Initiations Multiple Clinical Readouts Anticipated throughout 2022 and 2023 Operating...
Annexon Closes $130 Million Private Placement Extending its Operating Runway into the Second Half of 2025
11 juil. 2022 18h25 HE
|
Annexon Biosciences
BRISBANE, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Announces $130 Million Private Placement Financing
08 juil. 2022 07h00 HE
|
Annexon Biosciences
BRISBANE, Calif., July 08, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’s Disease
07 juin 2022 06h30 HE
|
Annexon Biosciences
ANX005 Demonstrated Full C1q Target Inhibition and Was Generally Well-Tolerated Disease Progression Stabilized in Overall Patient Population Through the Nine-month StudyRapid Improvement in Clinical...
Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference
02 juin 2022 06h30 HE
|
Annexon Biosciences
BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...